Twist Bioscience (TWST) Total Non-Current Liabilities (2018 - 2026)

Twist Bioscience has reported Total Non-Current Liabilities over the past 9 years, most recently at $220.4 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 42.13% to $220.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $220.4 million through Mar 2026, up 42.13% year-over-year, with the annual reading at $168.2 million for FY2025, 19.07% up from the prior year.
  • Total Non-Current Liabilities was $220.4 million for Q1 2026 at Twist Bioscience, up from $181.2 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $220.4 million in Q1 2026 and troughed at $141.2 million in Q3 2024.
  • The 5-year median for Total Non-Current Liabilities is $152.7 million (2023), against an average of $159.5 million.
  • Year-over-year, Total Non-Current Liabilities soared 831.33% in 2022 and then fell 13.01% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $163.6 million in 2022, then dropped by 13.01% to $142.3 million in 2023, then rose by 6.98% to $152.2 million in 2024, then increased by 19.06% to $181.2 million in 2025, then grew by 21.59% to $220.4 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Total Non-Current Liabilities are $220.4 million (Q1 2026), $181.2 million (Q4 2025), and $168.2 million (Q3 2025).